BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17227295)

  • 21. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
    McAlister VC; Mahalati K; Peltekian KM; Fraser A; MacDonald AS
    Ther Drug Monit; 2002 Jun; 24(3):346-50. PubMed ID: 12021624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production.
    Jiang H; Wynn C; Pan F; Ebbs A; Erickson LM; Kobayashi M
    Transplantation; 2002 Jun; 73(11):1808-17. PubMed ID: 12085006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect.
    Härtel C; Schumacher N; Fricke L; Ebel B; Kirchner H; Müller-Steinhardt M
    Clin Chem; 2004 Jan; 50(1):141-51. PubMed ID: 14709642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of allogeneic bone marrow cells in view of residual alloreactivity: sirolimus but not cyclosporine evolves tolerogenic properties.
    Timrott K; Vondran FW; Bektas H; Klempnauer J; Jäger MD
    PLoS One; 2015; 10(3):e0119950. PubMed ID: 25836261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T; Klupp J; Barten MJ; Christians U; Morris RE
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical results of sirolimus treatment in transplant models.
    Stepkowski SM
    Transplant Proc; 2003 May; 35(3 Suppl):219S-226S. PubMed ID: 12742499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
    Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
    Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine mRNA expression in tolerant heart allografts after immunosuppression with cyclosporine, sirolimus or brequinar.
    Tian L; Stepkowski SM; Qu X; Wang ME; Wang M; Yu J; Kahan BD
    Transpl Immunol; 1997 Sep; 5(3):189-98. PubMed ID: 9402685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells.
    Ahmed M; Venkataraman R; Logar AJ; Rao AS; Bartley GP; Robert K; Dodson FS; Shapiro R; Fung JJ; Zeevi A
    Ther Drug Monit; 2001 Aug; 23(4):354-62. PubMed ID: 11477316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
    Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
    Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo.
    Boldt A; Barten MJ; Sagner A; Mohr FW; Adams V; Dhein S; Gummert JF
    Transplantation; 2006 Aug; 82(3):422-7. PubMed ID: 16906043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A short course of cyclosporine immunosuppression inhibits rejection but not tolerance of rat liver allografts.
    Huang WH; Yan Y; De Boer B; Bishop GA; House AK
    Transplantation; 2003 Feb; 75(3):368-74. PubMed ID: 12589161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
    Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
    Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats.
    Stepkowski SM; Napoli KL; Wang ME; Qu X; Chou TC; Kahan BD
    Transplantation; 1996 Oct; 62(7):986-94. PubMed ID: 8878394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes.
    Rampino T; Ranghino A; Guidetti C; Gregorini M; Soccio G; Marasà M; Libetta C; Guida G; De Amici M; Dal Canton A
    Transpl Immunol; 2007 Jul; 18(1):32-6. PubMed ID: 17584600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.